Compare MSAI & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSAI | GTBP |
|---|---|---|
| Founded | 1995 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 12.4M |
| IPO Year | 2021 | 2016 |
| Metric | MSAI | GTBP |
|---|---|---|
| Price | $3.27 | $5.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.6K | ★ 54.5K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.03 | 3.75 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,551,000.00 | N/A |
| Revenue This Year | $45.92 | N/A |
| Revenue Next Year | $72.84 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.15 | $0.22 |
| 52 Week High | $7.94 | $287.50 |
| Indicator | MSAI | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 24.69 | 36.57 |
| Support Level | $0.22 | $0.22 |
| Resistance Level | $5.63 | $7.73 |
| Average True Range (ATR) | 0.33 | 0.62 |
| MACD | -0.08 | 0.43 |
| Stochastic Oscillator | 1.72 | 17.70 |
MultiSensor AI Holdings Inc builds and deploys integrated condition monitoring and early threat detection solutions through a unified edge-to-cloud software architecture, delivering AI-powered connected intelligence and analytics for asset reliability and performance. The Company's platform integrates multiple sensing modalities such as thermal, visual, and vibration to detect mechanical, electrical, and other modes of asset failure, enabling organizations operating high-throughput, automation-rich, and power-dense facilities to protect uptime, enhance safety, and extend the useful life of their critical assets.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.